GSK won FDA approval for Jideytro (zidesamtinib), its ROS1 inhibitor for ROS1-positive non-small cell lung cancer, ahead of the September 18 deadline as part of its Nuvalent acquisition. The treatment, showing a 44% response rate in trials, positions GSK to compete in lung cancer and supports ongoing development of additional Nuvalent assets like neladalkib and ris-rez.

Health· Jul 23, 2026

Facts from Wikidata (CC0).

entrectinib

compuesto químico

3miembros1here now

Pregunta a Genius Sitio

Sitio Diario

Feed Debates Acerca de

Sort by

Content type

Últimas noticias y debate sobre entrectinib

Sort by

Content type

Eentrectinib· Health · 9 sources · Jul 23, 2026Story

GSK earns FDA approval for Jideytro

Health· Jul 23, 2026

Facts from Wikidata (CC0).

entrectinib across IJR

Ask Genius by OpenServe about entrectinib Create in Studio Build a game Watch videos

About entrectinib

Entrectinib, vendido bajo el nombre de marca Rozlytrek, es un medicamento contra el cáncer utilizado para tratar el cáncer de pulmón de células no pequeñas positivo para ROS1 y tumores sólidos positivos para fusión de NTRK. Es un inhibidor selectivo de tirosina quinasa (TKI), de las quinasas receptoras de tropomiosina (TRK) A, B y C, oncogén C-ros 1 (ROS1) y quinasa de linfoma anaplásico (ALK).

members

here now

Coverage spread L0 / C75 / R25

Everything about entrectinib →

Live room · 1 here

Be the first in the room — members see you arrive.

Join the room

entrectinib across IJR

Ask Genius by OpenServe about entrectinib Create in Studio Build a game Watch videos